High efficiency latency and activation of herpes simplex virus in human cells.
Herpes simplex virus (HSV) exists in humans in a latent form that can be activated. To characterize the molecular basis of the cell-virus interactions and to analyze the state of the latent HSV genome, an in vitro model system was established. In this system a large fraction of the latently infected cells contain an HSV genome that can be activated. Cell survival was reduced minimally after repression of high multiplicity HSV type 1 (HSV-1) infection of human fibroblast cells with (E)-5-(2-bromovinyl)-2'-deoxyuridine in combination with human leukocyte interferon (IFN-alpha). A minimum of 1 to 3 percent of the surviving cells contained an HSV genome that could be activated either by human cytomegalovirus superinfection or reduction in incubation temperature.
D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology; D006561:Herpes Simplex / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D018139:Simplexvirus / Q000502:physiology*; D014775:Virus Activation; D014779:Virus Replication / Q000187:drug effects
D003561:Cytarabine; C020235:brivudine; D007372:Interferons; D001973:Bromodeoxyuridine